For a deeper look at what GLP-1 approval actually required, Meto's clinical overview of GLP-1 drugs provides useful context as does our recent piece on Foundayo (orforglipron), the first oral GLP-1 to reach approval
JAMA, vol
BPC-157 Capsules provide a convenient oral delivery format of the well-known regenerative peptide, designed for those seeking consistent, full-body recovery support
### Recommended: 5mg/mL (Most Common) | Vial Size | BAC Water to Add | Concentration | Volume per 0.5mg Dose | |-----------|-----------------|---------------|-----------------------| | 5mg | 1.0mL | 5mg/mL | 0.10mL | | 10mg | 2.0mL | 5mg/mL | 0.10mL | | 20mg | 4.0mL | 5mg/mL | 0.10mL | At 5mg/mL, each 10 units on an insulin syringe equals 0.5mg making dose calculations clean and straightforward
Understanding AOD 9604: The Basics A synthetic peptide, AOD 9604, was conceived with the intent to emulate specific fat-burning attributes of the human growth hormone, but without the associated side effects
As of 2026, the FDA allows licensed pharmacies to make these peptides with a prescription, but that is not the same as approving them as safe or effective